BridgeBio Pharma Inc (BBIO) Unusual Options Activity Today

Checking BBIO unusual options activity helps you spot when traders are making outsized bets on BridgeBio Pharma Inc before the broader market catches on. BridgeBio Pharma Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor BBIO unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching BBIO unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking BBIO unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and BBIO unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.

The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Catalysts rarely arrive without a footprint, and BBIO unusual options activity is often where that footprint shows up first. Our scanner tracks BridgeBio Pharma Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at BBIO unusual options volume on the call side or chasing put sweeps, BridgeBio Pharma Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.